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Abstract 
Background: There are several scales used to detect apathy in disease populations. 
Since apathy is a prevalent symptom in many neurodegenerative diseases, this is an 
especially important context in which to identify and compare scales.  
Aims: To provide an overview of apathy scales validated in generic and specific 
neurodegenerative disease populations, compare validation studies’ methodological 
quality and the psychometric properties of the validated apathy scales. 
Methods: A systematic review of literature was conducted of articles published 
between 1980 and 2013. The final articles selected for review were rated on 
methodological quality and the psychometric properties of the scales used were 
interpreted. 
Results: Sixteen articles validating apathy scales were included in the review, five in a 
generic neurodegenerative sample and eleven in specific neurodegenerative samples. 
The methodological quality of specific studies varied from Poor to Excellent. The 
highest quality, which had psychometrically favourable scales, were the Dementia 
Apathy Interview and Rating and the Apathy Evaluation Scale- Clinical version in 
Alzheimer’s Disease and the Lille Apathy Rating Scale in Parkinson’s disease. 
Generic neurodegenerative disease validation studies were of average methodological 
quality and yielded inconsistent psychometric properties. 
Conclusions: Several instruments can be recommended for use in some specific 
neurodegenerative diseases. Other instruments should either be validated or 
developed to assess apathy in more generic populations.  
Key words: apathy, rating scales, psychogeriatrics, dementia, motor disorders 
 
 
 
 
Introduction 
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Historically, apathy is reported to have undergone a transformation in its 
definition. Originally, rooted in apatheia, meaning without (a-) passion (-pathos), it 
was regarded as a virtue in Greek Stoic philosophy, allowing individuals to be more 
objective. However, the modern meaning of apathy has come to be regarded as 
undesirable and, as a part of the psychiatric field, can be a syndrome or symptom 
relating to disease. Clinically, as a behavior, apathy is most often characterised as a 
deficit in motivation, which is displayed through reduced interest, emotions and goal 
directed behaviors (Marin, 1996). Apathy has been found to have a variable 
relationship with various symptoms and experiences, such as depression and 
boredom. As a symptom, apathy has a variable association with depression dependent 
on the neurodegenerative disease (Levy et al., 1998). However, depression is 
expressed as negative and, in the case of bipolar depression, extremely positive affect 
(Levy et al., 1998), whereas, apathy is observed as emotional neutrality, where neither 
positive nor negative emotions are observed. Boredom, on the other hand, is a 
widespread human experience that is linked, through motivational elements, to 
apathy. However, research has shown them to be statistically distinct when measured 
by scales (Goldberg et al., 2011). This is due to apathy scales being designed to 
measure apathy as a symptom rather than a domain of normal motivational behavior.  
 
Apathy has been frequently observed as a symptom of neurodegenerative 
diseases (for review see van Reekum, Stuss and Ostrander, 2005; Chase, 2011) and is 
assessed by a variety of methods. Both clinically and in research, these methods often 
range from administration of measurement scales to observational ratings of 
behaviors by an experienced or trained individual. While specific methods of 
assessing apathy have guidelines to ensure that it is administered in a standardised 
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fashion, the problem is that there are many different methods to measure apathy. This 
creates uncertainty of which method would be most appropriate to measure apathy in 
a given pathological population. The utility of these methods are often based on 
previous studies, which have validated the measure in a specific pathological 
population. However, these methods and the studies validating them are seldom 
compared within literature.  
 
Since apathy is a common symptom in neurodegenerative disease, this is an 
important area in which to produce a comprehensive review of how apathy is 
measured both generally and for specific neurodegenerative diseases. It would also be 
beneficial to compare the validity and reliability of assessment methods, so that the 
highest quality, well-validated and reliable method can be chosen for a specific 
patient group. 
 
Apathy in neurodegenerative disease: 
Apathy is common in all types of dementia (Clarke et al., 2008) and most 
prominent in both Alzheimer’s disease (AD) and vascular dementia (VaD; Jonsson et 
al., 2010). In both small and large vessel VaD, apathy is a consistent symptom with 
negative prognostic and treatment implications (Staekenborg et al., 2010). In AD, 
apathy was found to occur in 61% to 92% of patients (e.g. Landes et al., 2005) with 
an almost equally high prevalence in frontotemporal dementia (FTD; e.g. Mendez et 
al., 2008). However, recent research has found differing apathy profiles which can 
distinguish between AD and FTD (Quaranta et al., 2012). This distinction between 
AD and FTD was also observed in functional impairments of activities of daily living, 
which could be associated with apathy level (Mioshi et al., 2009). 
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Apathy is also a prominent symptom in amyotrophic lateral sclerosis (ALS; 
Grossman et al., 2007; Girardi et al., 2011), the most common form of motor neurone 
disease (Goldstein and Abrahams, 2013). A large cohort study found that apathy was 
the most common behavioral symptom in ALS, occurring in 31% of patients (Witgert 
et al., 2010). Recent neuroimaging research in ALS has shown evidence of 
neuroanatomical correlates relating to apathy of abnormalities in the anterior 
cingulate cortex (Woolley et al., 2011). In a recent review of social cognition in ALS 
apathy was observed as the most prevalent, overlapping behavioral change in both 
ALS and FTD (Abrahams, 2011).  
 
In other motor disorders such as Parkinson’s disease (PD), over a third of 
patients have been found to exhibit apathy (Pedersen et al., 2009). Apathy may be 
predictive of cognitive decline and even dementia in PD (Dujardin et al., 2009) but 
may also have marked variability in its relation to the clinical presentation of PD 
(Dujardin et al., 2007).  
 
Apathy is also a persistent and progressive symptom across all stages of 
Huntington’s disease (HD; Thompson et al., 2012) with a variable prevalence 
reported between 34% and 76% associated with stage of disease (van Duijn et al., 
2007). A study comparing HD gene mutation carriers versus non-carriers found that 
the latter had 0% prevalence compared to carriers who had 32% prevalence (van 
Duijn et al., 2010). Functional decline was also found to be greater in HD patients 
with apathy, independent of motor or cognitive symptoms (Hamilton et al., 2003). 
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Due to this variable prevalence of apathy in these neurodegenerative diseases, this 
review focuses on apathy as a symptom of these specific diseases.  
 
Emerging concepts: 
Apathy is conceptualised by the measurement scales associated with it. It is 
originally defined by a substructure of cognition, behavior and emotion (Marin et al., 
1991) but is measured as singular concept, with specified clinical cut-offs dependent 
on the scale. 
 
A previous review by Clarke et al. (2011) looked at all the different 
measurement methods to assess apathy in research and clinical practice and found that 
most used rating scales or scale-based interviews. These scales were self-assessments, 
informant-based or clinical semi-structured interviews for patients or informants. The 
studies reviewed included a range of pathological populations with variable 
aetiologies (Clarke et al., 2011). However, Clarke et al’s review did not directly 
examine apathy as a symptom of specific neurodegenerative diseases and was not a 
systematic review of literature. The present review follows the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA; Moher et al., 2009) 
criteria to methodologically identify the quality of existent apathy scales and define 
which scales have been validated in neurodegenerative diseases. As apathy occurs as 
a symptom in a majority of neurodegenerative diseases (for review see van Reekum, 
Stuss and Ostrander, 2005; Chase, 2011) it is important to examine methods of apathy 
assessment that can identify apathy as a symptom in any neurodegenerative disease. 
Furthermore, as previously mentioned, patients with specific neurodegenerative 
diseases, such as HD and AD, exhibit apathy in variable prevalence. So it is important 
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to classify scales that were specifically designed, and therefore only validated, in 
specific neurodegenerative disease so that they may be used as such in the future. This 
will allow for identification of apathy scales that are neurodegenerative disease 
generic and specific. This will result in recommendations for suitable apathy scale 
choices to be made in future research and clinical practice in a disease group where 
apathy is a prevalent symptom. 
 
Quality, Validity and Reliability: 
The methodology and the measures used within a research study are important 
determinants of article quality. Individual articles employ different patient groups, 
inclusion and exclusion criteria, index tests and reference or gold standards of 
diagnosis, all of which are described with different levels of detail. Due to this 
variation, we considered it important to use a standardized tool for quality assessment 
of each study.  
 
In addition, we considered the psychometric properties reported by each study 
of the specific apathy instrument, which are commonly presented in terms of validity 
and reliability. Validity is best described as accuracy of an instrument, and can be 
defined through content, concurrent, convergent, congruent and discriminant or 
divergent. Content validity relates to the design of a measure and whether the 
instrument is measuring what it is aiming to measure. Concurrent, convergent or 
congruent validity are often grouped together as measuring construct validity and 
measure whether the instrument correlates with other well-validated methods of 
detection. This method of detection is known as a gold or reference standard. In terms 
of apathy, a gold standard would be the diagnosis of apathy by one or two trained 
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psychiatrists via observation, a structured or semi structured clinical interview. 
Discriminant or divergent validity is also an important psychometric property and is 
where two components, or constructs, that are theoretically unrelated are actually 
shown to dissociate. With symptomatic apathy, this behavioral component is often 
depression (Levy et al., 1998), which is due the emotional nature of patients with 
depression and, conversely, the emotionally neutral nature of apathetic patients. This 
apathetic component also differentiates it from exhilarating happiness observed in 
elation, the uncomfortable uneasiness of anxiety and excessive agitation associated 
with irritability. These behavioral components can also be used to determine 
discriminant validity. 
 
Reliability is best defined as the consistency of the measure. This relates to the 
replicability of findings independent of how accurate they are. This can be determined 
through between-item correlations of the specific measure, which is known as internal 
consistency reliability and usually measured by Cronbach’s alpha (Cronbach, 1951). 
Test-retest reliability is another form where the relationship between responses to the 
measure over several different time periods is recorded and correlated. Another form 
of reliability is inter-rater based, which examines whether two, or more informants or 
interviewers responses or scores agree. 
 
Both validity and reliability are important determinants of an assessment 
scale’s utility and a good apathy measure should embody both of these characteristics 
measured in the same sample. Therefore, the focus of this review will be on studies 
that examine both the validity and reliability of scales. However, there are no gold 
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standards of interpretation regarding validity and reliability psychometric statistics, 
therefore previously used guidelines were adopted to categorise them. 
 
Study aims: 
Based on the above points and issues, the aims of this review are: 
 
1. To determine apathy assessment scales that have been validated in 
neurodegenerative populations 
2. To determine neurodegenerative generic and neurodegenerative specific 
apathy assessment scales 
3. To quantify the methodological quality of the apathy assessment validation 
studies 
4. To compare reliability and validity statistics of each apathy assessment scale 
as to establish suitable neurodegenerative generic and specific apathy 
assessment methods 
 
Methods 
This systematic review was conducted following the PRISMA guidelines 
(Moher et al., 2009). The competed checklist can be found in the Supplementary 
materials (see figure S1). 
 
Eligibility criteria 
Only articles, abstracts and letters limited to English language publications 
between 1980 and 2013 containing human participants, aged 18 or older were 
screened.  
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Information Sources 
The main search was conducted on 31 December 2013. The electronic 
databases used were EMBASE, PSYCHINFO, MEDLINE and PUBMED. 
 
Search criteria 
Through the use of Boolean operators, the database searches were restricted to 
an apathy term (‘Apathy’ or ‘Motivation’ or ‘Amotivation’), neurodegenerative 
disease term (‘Dementia’ or ‘Alzhemier Disease’ or ‘Alzheimer’s Disease’ or 
‘Multiinfarct Dementia’ or ‘Vascular Dementia’ or ‘Frontotemporal Dementia’ or 
‘Semantic Dementia’ or ‘Parkinson Disease’ or ‘Parkinson’s Disease’ or ‘Motor 
Neuron Disease’ or ‘Amyotrophic Lateral Sclerosis’ or ‘Huntingtons Disease’ or 
‘Huntingtons Chorea’), a scale term (‘Rating Scale’ or ‘Rating Scales’ or ‘Summed 
Rating Scale’ or ‘Psychological Rating Scale’ or ‘Psychiatric Status Rating Scale’ or 
‘Questionnaire’ or ‘Questionnaires’ or ‘Measurement’) and a validity or reliability 
term (‘Reliability’ or ‘Validity’ or ‘Test Reliability’ or ‘Interrater Reliability’ or 
’Statistical Reliability’ or ‘Test Validity’ or ‘Statistical Validity’). 
 
Study selection 
After applying the above mentioned search criteria and eligibility criteria, 
duplicate articles were removed. Study selection was conducted in two main stages 
following the electronic search. In the first stage, two authors (R.R. and C.H.) went 
through the titles and abstracts independently, selecting which abstracts to include in 
the next stage, exclude from the next stage and which were ambiguous or disagreed 
upon by the aforementioned two authors. Inclusion was based on the following: study 
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involved a neurodegenerative disease population, used scalar or quantifiable methods 
of assessing apathy levels, and recorded both validity and reliability statistics. The 
ambiguous or disagreed upon abstracts were then forwarded to the third author (J.S.) 
who made suggestions, of inclusion, exclusion or examination of whole articles. 
 
In the second and final stage, the selected abstracts were then examined as full 
articles by authors R.R. and C.H., independently. These were classed as include in the 
review, exclude from the review and ambiguous or disagreed upon by authors R.R. 
and/or C.H. Articles that were included in the review had to meet the same criteria as 
in the first stage but authors were additionally asked to record the neurodegenerative 
disease assessed, apathy assessment methods used and validity and reliability 
statistics produced. In all cases, the authors had to provide reasons for exclusion or 
ambiguity. Advice from the third author, J.S., was sought once again for ambiguous 
or disagreed upon articles. A consensus had to be reached for articles that were to be 
used in the review. 
 
Neurodegenerative disease generic and specific study grouping 
The final articles were then grouped based on whether the study population 
assessed for apathy was neurodegenerative disease generic (e.g. containing a mixture 
of AD and PD patients) or specific (e.g. containing only AD patient) as to determine 
the utility in each group. 
 
Quality Assessment 
The final articles selected for review were subjected to the Quality Assessment 
of Diagnostic Accuracy Studies (QUADAS) checklist (Whiting et al., 2003, see Table 
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1). This was used to determine the quality of each article. The target condition was 
apathy, the index test was the method by which apathy was assessed and the reference 
standard was the method by which apathy was diagnosed and, therefore, the 
validation method for the index test.  
 
Items 1 to 5, 7 to 9 and 13 to 14 from the QUADAS were found to be 
applicable for determining quality of methodology and used for this particular review 
(see Table 1). Some QUADAS items (6 and 10 to 12) were not included due to their 
lack of applicability for assessing bias in psychiatric symptom scale validation 
studies, such as apathy. Items 1 and 2 relate to variability of the studies in the sample 
assessed and which impacts on the generalizability of findings to the study 
population. Items 3 to 5, 7 and 14 examine methodological rigour and bias, which 
influences the validity of the study results and, therefore, the validity of the scale. 
Finally, items 8, 9 and 13 determined the quality of reporting of methodology. Items 
were answered ‘yes’, ‘no’ or ‘unsure’ after close examination of the articles by author 
R.R. 
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Table 1. QUADAS items for quality review 
Items 
1 Was the spectrum of patients representative of the patients who will receive the test in 
practice? 
2 Were selection criteria clearly 
described?
  
3 Is the reference standard likely to correctly classify the target condition? 
4 Is the time period between reference standard and index test short enough to be 
reasonably sure that the target condition did not change between the two tests? 
5 Did the whole sample or a random selection of the sample, receive verification using a 
reference standard of diagnosis? 
7 Was the reference standard independent of the index test (i.e. the index test did not 
form part of the reference standard)? 
8 Was the execution of the index test described in sufficient detail to permit replication 
of the test? 
9 Was the execution of the reference standard described in sufficient detail to permit its 
replication? 
13 Were uninterpretable/ intermediate test results reported? 
14 Were withdrawals from the study explained? 
Target condition= Apathy; Index test= Apathy assessment method; Reference 
standard= Apathy diagnosis method 
 
There is no standardized scoring system for the QUADAS. Therefore, we 
categorised each study based on the number of QUADAS items that were answered 
‘yes’ to. The categorisation was as follows; 9 or 10 items was classed as Excellent, 7 
or 8 was Good, 4 to 6 was Adequate, 2 to 3 items was Poor and 0 to 1 was considered 
Unacceptable.  
 
Interpretation of psychometric properties 
We have provided a table of guidelines for interpreting internal consistency 
and correlation coefficients in relation to validity and reliability statistics (see table 
S1). This was adapted based on Hermans, van der Pas and Evenhuis’ (2011) review 
paper of anxiety scales. However, we have updated the interpretation of internal 
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consistency (George and Mallery, 2003) and Kappa statistic (Viera and Garrett, 
2005).  
 
Results 
Systematic review 
Figure 1 illustrates the review process in a flowchart. From the databases 
listed and using the search criteria specified earlier, a total of 168 studies were 
identified. When the eligibility criteria were applied prior to the first stage, 21 articles 
were removed, leaving 147 articles. After identifying and removing 31 duplicate 
articles, this left 116 studies eligible for the first stage of study selection; title and 
abstract screening. These included a variety of neurodegenerative populations that 
assessed apathy using various methods. 
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168 hits from 
database searches 
21 articles removed (non-English, non-
human, participants age 19+ published 
before 1980) 
 
147 articles remain 
31 duplicate articles removed 
 
116 study articles 
 
28 articles retrieved 
for detailed evaluation 
 
88 articles excluded based on 
Title/Abstracts: 
- 47 not a reliability/validity studies 
- 34 not relating to apathy 
measurement 
- 4 not relating to apathy measurement 
AND not a neurodegenerative 
population study 
- 2 not a neurodegenerative population 
study  
- 1 previous review paper in the field 
 16 hits 
PSYCHINFO 
database 
search 
23 hits EMBASE 
database search 
94 hits MEDLINE 
database search 
35 hits PUBMED 
database search 
12 extra articles 
identified: 
- 11 from reference lists 
- 1 from Google Scholar 
14 articles excluded: 
- 5 only reported validity 
- 5 only reported reliability 
- 3 not apathy scales 
- 1 insufficient patient information 
 
 
 Further 10 articles excluded: 
- 6 only reported reliability 
- 2 no validity and reliability 
- 1 only reported validity 
- 1 no neurodegenerative patients 
 
16 included in review 
 Figure 1. Flowchart of review process 
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In the first stage of study selection, of the 116 studies, 88 were not relevant or 
excluded: 47 were not reliability/validity studies, 34 were not studies that related to 
apathy measurement, four were not studies that related to apathy measurement and 
were not conducted in a neurodegenerative population, two were not conducted in a 
neurodegenerative population and one was a previous review paper in the field 
(Clarke et al., 2008). This left 28 studies to be included for detailed evaluation. A 
further 12 articles were identified through Google Scholar and reference lists and 
included for detailed evaluation, resulting in a total of 40 studies for detailed 
evaluation. 
 
The second stage of study selection, of the 40 studies, 24 articles were 
excluded: 11 only reported validity for the apathy measurement, six only reported 
reliability for the apathy measurement, three were not apathy scales, two did not 
report validity and reliability of the apathy measurement, one had insufficient patient 
information and one was not conducted in a neurodegenerative population. 
 
Table 2 shows, in total, 16 studies were included in the review. Seven of these 
articles validated English versions of a scale (Starkstein et al. 1992, Cummings et al. 
1994, Kaufer et al. 2000, Strauss et al. 2002, Clarke et al. 2007, Zahodne et al. 2009, 
de Medeiros et al. 2010). 
 
The review of methodological quality of each study by the chosen QUADAS 
criteria is shown in Table 2. There was a range of Poor to Excellent quality studies 
with the modal quality rating being Adequate.  
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No studies stated explanations for patient withdrawals; a large proportion of 
which were unclear about their withdrawals and the remainder did not state any 
explanations. However, almost all of the studies used a reference standard that was 
independent of index test for their validation study (see figure S2). There were five 
studies that examined apathy scales or subscales in a generic neurodegenerative 
disease sample and 11 that examined them in specific neurodegenerative disease 
samples. 
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Table 2. Methodological quality ratings of review studies 
Author (Year) Instrument Generic/ 
Specific 
1  2 3 4 5 7 8 9 13 14 Overall 
Quality 
Clarke et al. (2007) Self, Informant and Clinical Apathy Evaluation Scale (AES-S/I/C) Generic N U Y N Y Y Y Y N N Adequate 
Cummings et al. 
(1994) 
Neuropsychiatric Inventory- Apathy (NPIa) Generic Y Y U U U Y Y U U N Adequate 
de Medeiros et al. 
(2010) 
Neuropsychiatric Inventory- Clinical Rating Scale- Apathy (NPIa-
C) 
Specific Y Y Y N Y Y U Y U U Adequate 
Dujardin et al. 
(2008) 
Informant based Lille Apathy Rating Scale (LARS-i) Specific Y U Y U Y Y Y Y U N Adequate 
Hseih et al. (2012) Clinical Apathy Evaluation Scale (AES)  Specific Y Y Y U Y Y Y Y U N Good 
Kaufer et al. (2000) Brief Clinical Neuropsychiatric Inventory- Apathy (NPIa-Q) Specific U U Y U Y N Y Y U U Adequate 
Leontjevas et al. 
(2012) 
Abbreviated Apathy Evaluation Scale (AES-10) Generic N U Y N Y N Y Y U U Adequate 
Lueken et al. 
(2007) 
Abbreviated Apathy Evaluation Scale (AES-10) Generic N U Y N Y N Y Y U U Adequate 
Malakouti et al. 
(2012) 
Farsi Neuropsychiatric Inventory- Apathy (F-NPIa)  Specific N Y N U U Y Y Y U U Adequate 
Pedersen et al. 
(2012) 
Starkstein Apathy Scale (SAS) Specific Y N N U N U Y U Y U Poor 
Politis et al. (2004) Hellenic Neuropsychiatric Inventory- Apathy (H-NPIa) Specific Y Y N N Y Y Y Y Y U Good 
Robert et al. (2002)  Apathy Inventory (AI) Generic Y Y U U Y Y Y Y U N Adequate 
Sockeel et al. 
(2006) 
Lille Apathy Rating Scale (LARS) Specific Y Y Y U Y Y Y U Y U Good 
Starkstein et al. 
(1992) 
Apathy Scale (SAS) Specific Y N U N N Y Y N N U Poor 
Strauss et al. 
(2002) 
Dementia Apathy Interview and Rating (DAIR) Specific Y Y Y Y Y Y Y Y Y U Excellent 
Zahodne et al. 
(2009) 
Lille Apathy Rating Scale (LARS) Specific U Y Y U Y Y Y Y U U Adequate 
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Generic neurodegenerative disease scales 
 
Table 3. Apathy scale psychometric properties in generic neurodegenerative disease studies 
Apathy 
Measure 
Author 
(Year) 
Type of 
measure 
Patient Group Patient N Internal 
Consistency 
Reliability 
Validity Statistic Reliability Statistic Quality 
Rating 
AES-
S/I/C 
Clarke et 
al. (2007) 
Self 
Report, 
Informant 
Report and 
Clinical 
Patient 
Interview 
55.2% AD, 14.3% 
mixed dementia 
(possible AD and 
possible lewy body 
dementia), 9.5% 
lewy body 
dementia, 5.7% 
VaD, 5.7% mixed 
dementia (AD and 
VaD), 4.8% FTD, 
4.8% other 
dementia 
 
 
121 
(diagnosis 
ascertained 
for 105 
participants) 
Crohnbach’s 
alpha (of 
factors 
derived from 
FA): 
 
AES-S 
Apathy factor 
= 0.884 
Other factor = 
0.410 
 
AES-I 
Apathy factor 
= 0.895 
Interest factor 
= 0.881 
 
AES-C 
Apathy factor 
= 0.864 
Interest factor 
= 0.908 
Convergent (NPIa 
Frequency x Severity): 
AES-S r = 0.22 (p<0.05) 
AES-I r = 0.49 (p<0.01) 
AES-C r = 0.27 (p<0.01) 
 
Discriminant (NPId): 
AES-S r = 0.23 (p<0.01) 
AES-I r = 0.22 (p<0.01) 
AES-C r = 0.18 (NS) 
 
Discriminant (NPIanx): 
AES-S r = 0.20 (NS) 
AES-I r = 0.30 (NS) 
AES-C r = 0.17 (NS) 
 
- Adequate 
NPIa Cummings 
et al. 
(1994) 
Informant 
Interview 
AD, Probable VaD 
and other 
dementias 
Concurrent 
validity study 
= 40 
Cronbach’s 
alpha 
(Frequency 
and severity): 
Content (Delphi Panel: 
10 national and 
international experts in 
geriatric psychiatry, 
behavioural neurology 
Between rater 
agreement (2 
trained raters, from 
a pool of 4 
behavioural 
Adequate 
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Inter-rater 
reliability 
study = 45 
Test-retest 
reliability 
study = 20 
Within range 
of 0.87 to 
0.88 
and neuropsychology 
rating each subdomain 
between 1 and 4; well 
assessed and poorly 
assessed, respectively): 
NPIa screening question 
=1.3 
NPIa subquestions = 1.4 
neurology fellows, 
a geriatric 
psychiatry fellow, 
premedical student 
and behavioural 
neurologist): 
Frequency- 97.9% 
Severity- 89.4% 
 
Test-retest (“within 
3 weeks”) 
Frequency r = 0.74 
(p<0.001) 
Severity r = 0.68 
(p<0.01) 
AES-10 Leontjevas 
et al. 
(2012) 
Informant 
Interview 
Nursing Home 
Residents: 
  
42% no dementia, 
17% AD, 11% VaD, 
8% mixed 
dementia, 4% other 
dementia (Korsakov 
syndrome, Lewy 
Body dementia, 
dementia with PD, 
FTD and HD), 18% 
non specified 
dementia 
100 Cronbach’s  
-alpha = 0.95 
-standardized 
alpha = 0.95 
Congruent (NPIa 
Frequency x Severity): 
Spearman’s rho = 0.62 
(p<0.001) 
 
Discriminant (CSDD): 
Spearman’s rho = 0.27 
(p<0.05) 
 
- Adequate 
AES-10 Lueken et 
al. (2007) 
Informant 
Report 
Nursing Home 
Residents: 
 
7% no dementia, 
69% AD, 7% VaD, 
4% mixed 
dementia, 1% FTD, 
356 
(Subsample 
A = 178, 
Subsample B 
= 178) 
Subsample 
A+B 
Cronbach’s 
alpha = 0.92 
Subsample A+B 
Concurrent (AES-I): 
r = 0.97  
 
Subsample A 
Concurrent (NPIa): 
r = 0.61  
- Adequate 
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1% dementia with 
PD, 3% other 
nonclassified 
dementia, 8% MCI 
 
Discriminant (NPId): 
r = 0.07  
 
(GDS): 
r = -0.51  
 
Subsample B 
Concurrent (NPIa): 
r = 0.62 
 
Discriminant (NPId): 
r = 0.09  
 
(GDS): 
r = -0.58 
AI Robert et 
al. (2002)  
Informant 
Interview 
AND 
Patient 
Interview 
AD, PD, MCI 115 Informant 
Interview 
Cronbach’s 
alpha = 0.92 
Concurrent (NPIa 
Frequency x Severity): 
 
Informant interview 
Emotional Blunting r = 
0.01 (NS) 
Lack of Initiative r = 0.23 
(p<0.01) 
Lack of Interest r = 0.63 
(p<0.001) 
Global score r = not 
recorded 
 
Patient Interview 
Emotional Blunting r = 
0.04 (NS) 
Lack of Initiative r = 0.01 
(NS) 
Lack of Interest r = 0.26 
(NS) 
Between rater 
agreement (26 
psychiatrists, 
psychologists and 
medical students 
rating one 
videotaped 
response): 
Kappa coefficient 
for item scores and 
global score = 0.99 
 
Test-retest (“same 
day”): 
Kappa coefficient 
emotional blunting 
= 0.99 
Kappa coefficient 
lack of initiative = 
0.97 
Adequate 
Apathy scales in neurodegenerative conditions: a review 
 
Global score r = not 
recorded 
 
Discriminant (NPId 
Frequency x Severity): 
 
Informant interview 
Emotional Blunting r = 
not recorded 
Lack of Initiative r = 0.32 
(p<0.05) 
Lack of Interest r = 0.40 
(p<0.001) 
Global score r = 0.37 
(p<0.01) 
 
Patient Interview 
Emotional Blunting r = 
not recorded 
Lack of Initiative r = 0.37 
(p<0.01) 
Lack of Interest r = 0.31 
(p<0.05) 
Global score r = 0.42 
(p<0.001) 
Kappa coefficient 
lack of interest = 
0.99 
Kappa coefficient 
global score = 0.99 
NS= Not Significant; NPId= NPI depression/dysphoria; NPIanx= NPI anxiety; CSDD= Cornell Scale for Depression in Dementia
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Table 3. shows the descriptors and quality of apathy scale validation studies in 
generic neurodegenerative disease patient samples. All five studies were of Adequate 
methodological quality. 
 
The Apathy Evaluation Scale (AES) was originally developed and validated in 
English by Marin et al. (1991). It is made up of 18 items that assess emotional, 
behavioral and cognitive aspects of apathy through a 4-point Likert scale. The 
responses are coded to give one apathy score. The AES is available in Self report (S), 
Informant report (I) or Clinical patient interview (C) forms. The validation study by 
Clarke et al. (2007) looks at all three forms of the AES in a generic neurodegenerative 
dementia sample group. Convergent validity was measured through correlations with 
the NPIa, all of which were positive ranging from little or no correlation for the AES-
S and AES-C to a low correlation with the AES-I. Discriminant validity for AES-S, 
AES-I and AES-C when compared to the NPId showed little or no positive correlation 
and with the NPIanx, ranging from low positive correlation for the AES-S and C to a 
low correlation for the AES-I.  This study does not provide internal consistency 
values for each form of the AES. However, it has subdivided each available form of 
the AES in to two factors each, resulting in numerous internal consistency values. The 
two factors for the AES-I and AES-C were labelled Apathy and Interest. For the AES-
I the Interest factor showed good internal consistency and the Apathy Factor showed 
excellent internal consistency. The AES-C showed a good internal consistency for the 
Apathy Factor and an excellent internal consistency for the Interest factor. The AES-
C showed a differing factor structure labelled Apathy and Other, with internal 
consistencies that are good and unacceptable, respectively. 
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Lueken et al. (2007) developed the abbreviated Apathy Evaluation Scale 
(AES-10) in German as a shortened, 10-item version of the AES-I. The items were 
developed and, as stated in the study, translated in close cooperation with Dr Robert 
Marin, the original author of the AES. It is scored almost identically as the original 
AES, on a 4-point Likert scale. It was validated in a sample of Nursing home 
residents, of various neurodegenerative diseases, some of who did not have dementia. 
The internal consistency reliability was excellent. A high positive correlation between 
the AES-10 and NPIa in both subsample A and B showed good concurrent validity. 
This was further supported by a very high, positive correlation with the AES-C. The 
discriminant validity was show to be good through little or no positive correlation 
between the AES-10 and the NPId in both subsamples. Furthermore, a moderate, 
negative correlation was observed between the AES-10 and the GDS.  
 
A more recent study also looked at the Dutch version of the AES-10 in 
Nursing home residents, almost half of which were non demented (Leontjevas et al., 
2012). As with the previous study, the internal consistency was shown to be excellent. 
For congruent validity, the AES-10 and NPIa showed a moderate positive correlation 
and when compared to a depression measure (CSDD), there was a little or no positive 
correlation, showing good discriminant validity.  
 
The Neuropsychiatric Inventory (NPI; Cummings et al., 1994) is a 12 domain 
Informant interview that assesses behavioral disturbances in various diseases. 
Originally developed in English, it measures apathy via the NPI apathy/indifference 
(NPIa) domain firstly with a screening question to determine the presence of these 
behaviors (Yes/No/NA answers). This is followed by eight subquestions to determine 
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the characteristics of apathy (Yes/No answers). The frequency of the NPIa domain is 
rated on a 4-point Likert scale along with a 3-point Likert scale for severity. 
Frequency and severity are then multiplied to give a final NPIa domain score. The 
internal consistency was difficult to determine specifically for the NPIa due to lack of 
detailed reporting in the Cummings et al. (1994) study. However, based on the range 
of values provided in the article, the internal consistency of the NPIa was good. A 
Delphi panel determined content validity by rating whether screening question and 
sub-questions captured the essential elements of behavior. For the NPIa, they rated 
both as close to being ‘assessed well’. Inter-rater agreement and test-retest reliability 
for frequency was also found to be high with a further moderate test retest for 
severity. 
 
The Apathy Inventory (AI; Robert et al., 2002) was developed and validated 
in French to assess global and subdomain apathy (emotional blunting, lack of 
initiative and lack of interest). It is a three item scale (one item for each domain) and 
is has been validated as a Self report and Informant interview. The Self report AI 
firstly has the patient assess their own behavior for each item (Yes/No) and then asks 
them to bisect a line in relation to the severity of their behavior that spans from mild 
to severe on a covert 12 point scale only know to the scorer. These three item 
severities are then added to give a composite apathy score. The Informant report is 
similar to the NPIa, recording whether the behaviors are displayed (Yes/No), 
frequency of behavior on a 4-point Likert scale along and severity of behavior on a 3-
point Likert scale. Again, frequency and severity are multiplied to give a numeric 
apathy level for each subdomain, which are then added to give a composite apathy 
level. The internal consistency for the informant interview was excellent. The NPIa 
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generally held little or no to low positive correlations with AI subdomains, with only 
positive, moderate correlation with the informant Lack of Interest subdomain. There 
were no record of the correlation between the NPIa and the AI global scores. 
Discriminant validity determined by the relationship the NPId and the AI (global and 
subdomains), which showed low to moderate positive correlations. The between rater 
and test retest reliability was almost perfect for the global and subdomain scores. 
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Specific neurodegenerative disease scales 
 
Table 4. Apathy scales psychometric properties in specific neurodegenerative disease patient populations 
Apathy 
Measure 
Study Type of 
measure 
Patient 
Group 
Patient 
N 
Internal 
Consistency 
Validity Statistic Reliability Statistic Quality 
Rating 
NPIa-C de 
Medeiros 
et al. 
(2010) 
Informant 
Interview 
Mild to 
severe 
Probable 
AD 
128 - Convergent validity (AES-I): 
Frequency x Severity Pearson’s r = 
0.22 
 
Inter-rater (ICC; 2 
independently trained 
raters): 
NPIa-C subquestions 
range from 0.74 to 
0.89 
Adequate 
LARS-i Dujardin et 
al. (2008) 
Informant 
Interview 
Probable 
PD 
60 Cronbach’s 
between-item 
-alpha = 0.872 
-standardized 
alpha = 0.877 
Concurrent (AES-I): 
Global score r = 0.850 (p<0.001) 
 
Concurrent (AES-C): 
Global score r = 0.811 (p<0.001) 
 
Concurrent (LARS): 
Global score r = 0.814 (p<0.001) 
Inter-rater (ICC, 2 
clinician 
interviewers): 
Global score = 0.966 
(p<0.001) 
 
Test-retest (“few days 
later”): 
Global score r = 
0.960 
Adequate 
AES-C Hseih et al. 
(2012) 
Informant 
Interview 
Mild to 
moderate 
AD 
144 Cronbach’s 
alpha = 0.85 
Convergent (NPIa Frequency x 
Severity): 
Pearson’s r = 0.61 (p<0.001) 
 
Discriminant (NPId and NPIe, both 
Frequency x Severity): 
NPId Pearson’s r = 0.16 (NS) 
NPIe Pearson’s r = -0.46 (p<0.001) 
Test-retest (“3 day 
period”): 
Pearson’s r = 0.89 
Good 
NPIa-Q Kaufer et 
al. (2000) 
Informant 
Report  
Possible 
and 
probable 
AD 
60 - Convergent (NPIa): 
Spearman’s rho = 0.85 (p<0.0001) 
Test-retest (“same 
day”): 
Pearson’s r = 0.80 
(p<0.0001) 
Adequate 
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F-NPIa Malakouti 
et al. 
(2012) 
Informant 
Interview 
Dementia 100 Cronbach’s 
alpha (severity) 
= 0.82 
Concurrent (PANSS): 
Frequency x Severity Pearson’s r = 
0.6-0.7 (p<0.001) 
Inter-rater (ICC, 2 
trained psychiatrist 
raters): 
Frequency Pearson’s 
r = 0.85 (p<0.001) 
 
Severity Pearson’s r 
= 0.83 (p<0.001) 
 
Frequency x Severity 
Pearson’s r = 0.87 
(p<0.001) 
 
Test-retest (“two 
weeks”): 
Frequency Pearson’s 
r = 0.90 (p<0.001) 
 
Severity Pearson’s r 
= 0.90 (p<0.001) 
 
Frequency x Severity 
Pearson’s r = 0.76 
(p<0.001) 
Adequate 
SAS Pedersen 
et al. 
(2012) 
Self 
Report 
PD 194 Cronbach’s 
alpha = 0.69 
Discriminant (MADRS): 
Spearman’s rho = 0.25 (p<0.01) 
- Poor 
H-NPIa Politis et al. 
(2004) 
Informant 
Interview 
AD 29 Cronbach’s 
alpha 
(Frequency x 
Severity): 
Within range of 
0.69 to 0.72 
Concurrent (BPRS): 
Frequency x Severity Pearson’s r = 
0.48 (p<0.001) 
- Good 
LARS Sockeel et 
al. (2006) 
Patient 
Interview 
Probable 
PD 
159 Cronbach’s 
standardized 
alpha 
Concurrent (AES): 
Global score r = 0.87 
Inter-rater (ICC, 2 
clinician raters): 
Global score r = 0.95 
Good 
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-between item 
= 0.80 
-between 
subscale = 0.74 
Intellectual curiosity subscale r = 
0.84 
Action Initiation subscale r = 0.65 
Emotion subscale r = 0.44 
Self awareness subscale r = 0.15 
 
Test-retest 
(“approximately four 
months”): 
Global score r = 0.98 
SAS Starkstein 
et al. 
(1992) 
Self 
Report 
Idiopathic 
PD 
50 Cronbach’s 
alpha = 0.76 
Convergent (Neurologist blind 
rating): 
Rated 6 apathetic and 6 apathetic 
with apathetic patients having 
significantly higher SAS score 
(apathetic SAS mean=14.8, SD=5.7; 
non-apathetic SAS mean=5.5, 
SD=2.2; t(10)=3.70, p<0.001) 
Inter-rater (2 raters): 
r = 0.81 (p<0.01) 
 
Test-retest (“1 week 
apart”): 
r = 0.90 (p<0.01) 
Poor 
DAIR Strauss et 
al. (2002) 
Informant 
Interview 
Possible 
and 
probable 
AD 
100 Cronbach’s 
alpha = 0.89 
Convergent (Clinical ratings; Nurse, 
Physician and Neuropsychologist 
technician): 
r = 0.40, 0.31 and 0.46, respectively 
 
Discriminant (BRSD-d): 
r = 0.08 
Inter-rater (2 trained 
raters, one interviews 
one rates audiotape 
of interview): 
100% agreement 
 
Test-retest (“an 
average of 56 days”): 
r = 0.85 (p<0.001) 
Excellent 
LARS Zahodne et 
al. (2009) 
Patient 
Interview 
Probable 
idiopathic 
PD 
71 Cronbach’s 
standardized 
alpha = 0.82 
Convergent (SAS): 
Global score r = 0.62 (p<0.001) 
Intellectual curiosity subscale r = 
0.61 (p<0.001) 
Action Initiation subscale r = 0.42 
(p<0.001) 
Emotion subscale r = 0.33 (p<0.01) 
Self awareness subscale r = 0.229 
(NS) 
 
Inter-method agreement (ICC; SAS): 
Global score = 0.75  
 
Divergent (BDI-II): 
- Adequate 
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Global score r = 0.45 (p<0.001) 
 
Inter-method agreement (ICC; BDI-
II): 
Global score r = 0.62 (p<0.001) 
 
NS= Not Significant; ICC= Intra-class correlation NPId= NPI depression/dysphoria; NPIanx= NPI anxiety; NPIe= NPI elation/euphoria; PANSS= 
Positive and Negative Symptoms Scale; MADRS= Montgomery-Aasberg Depression Rating Scale; BPRS= Brief Psychiatric Rating Scale; BRSD-d= 
Behavior Rating Scale for Dementia- Depression subscale; BDI-II= Beck Depression Inventory II
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Table 4 shows the different apathy scale validation studies in specific 
neurodegenerative disease patient samples, with descriptors and quality rating for 
each. The 11 studies ranged from Poor to Excellent quality. 
 
The NPI has been translated in to Greek (Hellenic; Politis et al., 2004) and a 
Persian language (Farsi; Malakouti et al., 2012) and validated in AD and generic 
dementia populations. Both are administered and scored in the same way as the 
original NPIa (Cummings et al., 1994). The Hellenic NPIa (H-NPIa) was translated 
by two bilingual psychiatrists from English to Greek and then independently 
translated back to English by one other psychiatrist. The quality of the study was 
classed as Good. The H-NPIa frequency x severity internal consistency fell within a 
range of questionable and acceptable with no further reliability reported. The 
concurrent validity between the apathy factor derived from the BPRS and the H-NPIa 
showed a low positive correlation. 
 
The Farsi NPIa (F-NPIa) was also translated by two bilingual psychiatrists 
from English to Farsi and then back-translated to English independently by two other 
bilingual psychiatrists. It was then validated in an unspecified dementia patient 
sample. The methodological quality of the study was classed as Adequate. However, 
the internal consistency was reported of the F-NPIa was good. The concurrent was 
determined against the PANSS, which was found to be of a high correlation. The 
reliability of the scale was good, with an excellent inter-rater intra-class correlation 
coefficient (ICC) and the test retest correlation coefficient was good.  
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In addition to the NPI translations above, several revised versions have been 
developed. The Brief Clinical NPI (NPI-Q: Kaufer et al., 2000), developed in English, 
is scored identically to the NPI but differs in administration method in that it is an 
informant report measure. The informants are asked to fill in the NPI-Q about the 
patient. The original validation study by Kaufer et al. (2000) recruited AD patients 
and was found to be of Adequate quality. While there was no report of the internal 
consistency for the NPI-Q apathy (NPIa-Q), the test-retest reliability correlation 
coefficient and convergent validity against the NPIa were both high positive 
correlations. 
 
The NPI Clinical rating scale (NPI-C; de Medeiros et al., 2010) is a revised 
version of the NPI with expanded domains and questions. It recognises the 
importance of the domain subquestions and rates frequency and severity through an 
item-by-item basis. It was validated in mild to severe probable AD patients by de 
Medeiros et al. (2010). This was a large-scale, cross-sectional validation study with 8 
participating countries (Argentina, Brazil, Canada, France, Greece, Hungary, Italy and 
America) and the NPI-C was translated to 7 languages (English, French, Greek, 
Hungarian, Italian, Portuguese and Spanish). The quality of this study was Adequate. 
It does not report internal consistency NPI-C apathy (NPIa-C) and the convergent 
validity against the AES-I showed little or no positive correlation. The inter-rater ICC 
for each of the subquestions of the NPIa-C ranged from good to excellent. 
 
The Starkstein Apathy Scale (SAS) was developed in English to assess apathy 
and validated in idiopathic PD patients (Starkstein et al., 1992). It is a condensed 
version of the AES, with only 14 items, scored by same 4-point Likert scale. It 
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defines itself as less comprehensive than the AES as to be less demanding for PD 
patients to complete. This study was of Poor quality with only an acceptable internal 
consistency for the SAS. The convergent validity was determined through a blind 
neurologist rating participants as apathetic or non-apathetic and then examining if 
their SAS scores are significantly different. They were found to be different, based on 
a sample size of 12 (six rated as apathetic, six rated as non-apathetic by the 
neurologist). The inter-rater reliability correlation coefficient was high and the test-
retest reliability correlation was very high. In a later study, the SAS was back-
translated in to Norwegian, the translation critically appraised by four of the authors 
and used in a Norwegian PD patient sample study (Pedersen et al., 2012). This study 
was also of Poor quality. This study reported a questionable internal consistency for 
the SAS with good discriminant validity due to little or no positive correlation with 
the MADRS. 
 
The Lille Apathy Rating Scale was originally developed in French and 
validated in patients with probable PD by Sockeel et al. (2006). It is a 33-item scale 
scored by a mixture of simple (Yes/No/NA) and Likert-type responses. It is composed 
of factor analytically derived subscales (Intellectual curiosity, Action initiation, 
Emotional and Self awareness), which are also summed to provide a global apathy 
score. The original validation study (Sockeel et al., 2006) was of Good quality.  It 
showed an acceptable (between subscale) to good (between item) internal 
consistency. Concurrent validity between the AES and LARS global score was high 
positive correlation, with LARS subscales being positive and ranging from little or no 
to high correlations. Inter-rater ICC and test retest reliability was found to be 
excellent. A study by Zahodne et al. (2009) of a slightly less Adequate quality further 
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validated LARS in English in probable idiopathic PD patients. It was showed to have 
a good internal consistency. For convergent validity, the SAS and the LARS global 
score correlated positively and moderately, with the subscales positively correlating 
from little to none to moderately. Additionally, the inter-method agreement (ICC) for 
the SAS and LARS global score was excellent. Divergent validity between the BDI-II 
and LARS global score was moderate and the ICC between the two was fair. 
 
Similarly to the LARS, the informant version of the LARS (LARS-i; Dujardin 
et al., 2008) was also developed in French and for validation in a PD population. 
Some items have been reworded to be suitable as a question for a patient’s informant. 
The administration and scoring methods are the same as the LARS. This particular 
study was of Adequate quality. The internal consistency for the LARS-i was shown to 
be good. The concurrent validity was good due to high positive correlations with the 
AES-I, AES-C and LARS. Inter-rater ICC and test retest reliability was excellent. 
 
The AES-C was further validated in mild to moderate severity AD patient 
sample (Hseih et al., 2012). It was back-translated to Taiwanese by two bilingual 
individuals. This was done until an agreement on the translation was reached between 
the two. In terms of quality, this study was classed as Good. The internal consistency 
for the AES-C was found to be good, with a moderate positive convergent validity 
against the NPIa. Discriminant validity against the NPId showed little to no 
correlation while against the NPIe it showed a low negative correlation. Test retest 
reliability correlation coefficient for the AES-C was good. 
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The Dementia Apathy Interview and Rating (DAIR) is an informant based 
interview, developed and validated in English to assess apathy in probable and 
possible cases on AD (Stuss et al., 2002). The assessment is a 16-question interview 
of the primary caregiver to assess the patient’s initiation behavior, interest and 
engagement in the environment through a 4-point Likert scale. This was the only 
study with Excellent methodological quality. The internal consistency of the DAIR 
was good with a generally low positive correlation in relation to clinician’s ratings, 
indicative of average convergent validity. It had little or no positive correlation with 
the BDRS, showing good discriminant validity against depression. It had a prefect 
inter-rater agreement with a high positive test-retest reliability correlation coefficient. 
 
Discussion 
This review systematically examines and provides an overview of the quality 
and psychometric properties of apathy scales, which have been used within 
neurodegenerative disease populations. Generally, most of the validation studies in 
this review were found to be of Adequate quality. Studies did not reach higher quality 
scores due to under described selection criteria, poor reporting of withdrawals from 
studies and a lacking of a good reference standard for diagnosing apathy. 
Nevertheless, their merits are that both the reference standards and the index tests for 
apathy were described in sufficient detail and, mostly, were independent of each 
other. 
 
Generic neurodegenerative scales 
The methodological quality of all the validation studies for the 
neurodegenerative generic scales was Adequate. This could have been improved with 
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better, defined selection criteria and comprehensive sampling to form more generic 
neurodegenerative patient groups. Therefore, it is important to examine the 
psychometric properties of each as to determine their practicality.  
 
The widely used NPI, developed and validated in a generic dementia sample 
by Cummings et al. (1994), is often used as a reference standard for other apathy 
measures. In the original validation study by Cummings et al. (1994), the design of 
the NPI was done using a Delphi panel of experts as to also determine content 
validity. They reported apathy as ‘well assessed’ but did not examine any other 
statistical validity criteria for the NPIa. Specific NPIa internal consistency was not 
reported but it was deduced as good, with a high between-rater agreement and good 
test-retest reliability. Most of the NPI subdomains were concurrently validated against 
existing instruments, whereas the NPIa domain was not. This lack of concurrent 
validity for the NPIa and a methodological rating of Adequate for this study create 
uncertainty of the robustness of this subscale’s ability to assess apathy. It is observed 
that many studies in this review have used the NPIa as a reference standard to validate 
their own methods of apathy assessment. As a consequence, perhaps these and any 
future validation studies using the NPIa as a reference standard should be considered 
and interpreted with caution.  
 
Similarly to the NPI, the AES is also considered as a validation reference 
standard. The original Marin et al. (1991) AES development and validation study was 
excluded in the earlier stage of this review due to a small sample size of the AD 
patients (N = 21 our of 123/ less than 20%) and included a very mixed patient sample 
of AD, stroke (left and right hemisphere), major depression and healthy controls. 
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Additionally, there was no specific AD reliability or validity information reported for 
the AES. However, a later study by Clarke et al. (2007) validated all forms of the 
AES against a generic dementia sample. The Clarke et al. (2007) study does not 
report reliability statistics and only factor analytically derived internal consistencies, 
making it difficult to interpret the scales as a whole. The convergent and discriminant 
validity was variable for all forms of the AES, resulting in unclear psychometric 
properties and, once again, therefore caution should be taken in considering its 
application as a reference standard for a neurodegenerative group.  
 
Two studies validating the AES-10 (Lueken et al., 2007, Leontjevans et al., 
2012), which is a shortened form of the AES, showed excellent internal consistency 
reliability and improved validity. Similar to the Clarke et al. study, the AES-10 
validation studies documented no other reliability statistics. It should, however, be 
noted that both studies recruited Nursing Home residents some of whom did not have 
a diagnosis of a neurodegenerative disease. The Lueken et al. (2007) was more 
representative of a neurodegenerative generic dementia population. However, the 
Leontjevas et al. (2012) study was not very representative of a neurodegenerative 
population because almost half of the participants had no signs of dementia. So while 
the AES-10 seems psychometrically strong, it could still benefit from further 
validation in a generic neurodegenerative disease population. 
 
Robert et al.’s (2002) AI validation study utilised a neurodegenerative generic 
patient sample containing AD, PD and mild cognitive impairment patients. While the 
AI was generally reliable, the inter-rater agreement, internal consistency, test-retest 
reliability being excellent, the validity was unclear. The concurrent validity was 
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underreported for the global score and showed an irregular relationship for the 
subscale scores. The association between the AI global and subscale scores with 
depression were stronger than that of the apathy measure. This stronger relationship 
with depression could indicate that the AI is not measuring the intended apathy, but 
rather some component associated with both apathy and depression, resulting in a lack 
of scale validity. 
 
Based on the results of this review, it is difficult to establish which scale is 
best for assessing apathy in a generic neurodegenerative disease population. There are 
various methodological flaws with the validation studies that affect the validity and 
reliability of the each scale. The main issue being that a generic neurodegenerative 
sample should involve all forms of neurodegenerative disease, not just various 
dementias (Cummings et al., 1994, Clarke et al., 2007) or a mixture healthy 
individuals and neurodegenerative patients (Lueken et al., 2007, Leontjevans et al., 
2012). Psychometrically, the AES-10 seems to be the most valid, but has not been 
applied in a purely neurodegenerative population. 
 
Specific neurodegenerative scales 
With regard to neurodegenerative specific apathy scales, the DAIR (Strauss et 
al., 2002) validation study has Excellent methodological quality for AD patients, due 
to lack of bias, a superior quality of methodological reporting and high 
generalizability of the results. This was closely followed by Good quality validation 
studies of the AES-C (Hseih et al., 2012) and the H-NPIa (Politis et al., 2004). Both 
had a representative sample and high generalizability of the results. However, the H-
NPIa was validated against a combination of BPRS subscales that were labelled as an 
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apathy factor, which is not a direct or established measure of apathy but rather a new 
construct. Additionally, when compared psychometrically, the H-NPIa reliability and 
validity was inferior to both the DAIR and the AES-C, partly due to insufficient 
reliability criteria reporting. When comparing the DAIR and the AES-C, both are well 
constructed, informant interviews completed by trained assessor with matched 
psychometric properties. Both validation studies note good internal consistency 
reliability but vary in the reporting of reliability and validity. The AES-C reports 
more detailed convergent and discriminant validity that are marginally superior to the 
DAIR. Conversely, the DAIR has better inter-rater agreement and test-retest 
reliability in comparison to the AES-C. Based on the psychometric properties of both 
these scales and the quality of their validation studies, either of these methods would 
be recommended for assessing apathy in AD patient populations. 
 
In relation to PD patients, both the SAS validation studies (Starkstein et al., 
1992, Pedersen et al., 2012) scored Poor on quality mostly due to the lack of 
methodological reporting and selection bias and also showed unfavourable 
psychometric validity and reliability. Only the Sockeel et al. (2006) LARS validation 
study was methodologically classed as Good quality due to minimised bias, detailed 
methodology reporting and generalizability of results. The internal consistency 
reliability was found to be acceptable which was supported by very good validity and 
reliability properties of the LARS global score. The high convergent validity and 
excellent reliability make this a good measure for apathy in PD. However, it does not 
examine discriminant or divergent validity against depression, which has been shown 
to occur with apathy in PD (Lieberman, 2006). A later validation study showed 
average discriminant validity against depression (Zahodne et al., 2009). 
Apathy scales in neurodegenerative conditions: a review 
 
 
In ALS, apathy is continually assessed using the Frontal Systems Behavior 
Scale (Grossman et al., 2007; Witgert et al., 2010) despite this scale not being 
validated in this neurodegenerative disease population. Additionally, research in HD 
has been conducted using scales that assess uncorroborated apathy that is a derivation 
of factor analysis (Thompson et al., 2012) or use scales that have not been validated 
in an HD sample (Hamilton et al., 2003, van Duijn et al., 2010). Therefore, no well-
validated scales to assess apathy within these two neurodegenerative disorders have 
been found. 
 
Strengths and limitations 
This review has been undertaken using a systematic methodology (PRISMA), 
ensuring that eligibility criteria, inclusion and exclusion criteria were carefully 
outlined and implemented. Secondly, all studies were included that met the criteria, 
which could be seen to reduce publication bias. Thirdly, through rating the validation 
studies for the scales on methodological quality using the QUADAS, allowed us to 
determine the quality of the validation procedure for the apathy scale in question. 
Finally, interpreting the psychometric statistics for reliability and validity of the scales 
(adapted from Hermans et al., 2011) allowed for a more standardized assessment. 
This resulted in more objectively driven recommendations for the most robust scale to 
be used in research or clinical practice to be made. 
 
A limitation for this study could be that we chose to exclude studies that 
reported just validity or reliability of apathy scales. However, a diagnostic instrument 
should be both reliable and valid at detecting a symptom (Kimberlin and Winetrstein, 
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2008) and both of these need to be demonstrated in the same sample (i.e. there is little 
point in having a scale that is reliable but not valid in one sample, and valid but not 
reliable in another). Therefore, by including validation studies that examine both of 
these criteria, we attempted to avoid partially validated scales that might not be 
suitable for assessment. Additionally, a systematic review using the PRISMA method 
requires “a clearly formulated question that uses systematic and explicit methods…” 
of identification, selection and critical appraisal of “relevant research” (Moher et al., 
2009). So by clearly defining those studies reporting complete results (i.e. reliability 
and validity statistics of a scale) improve the quality of this systematic review, 
making it possible for more credible, scale-utility recommendations to be made. 
 
Finally, it should be noted that apathy as a lack of motivation may manifest 
somewhat differently depending on the cultural context. Hence, caution is required 
when considering applying a scale validated in one country in another, especially if 
cultural norms are very dissimilar. 
 
Conclusion 
In conclusion, there are several recommended instruments to assess apathy for 
some specific neurodegenerative disease populations. The DAIR is a well-validated 
instrument in AD patients, shown to have very good psychometric characteristics, 
which is further supported by Excellent methodological quality of the validation study 
(Strauss et al., 2002). In relation to PD patient, the LARS validation study (Sockeel et 
al., 2006) showed that the global scoring of apathy was psychometrically strong, with 
further research needed to determine its subscalar structure and relationship with 
Apathy scales in neurodegenerative conditions: a review 
 
depression. Finally, scales should be developed and validated in diseases such as HD 
and ALS, which make apathy difficult to assess due to marked motor symptoms. 
 
This review did not find any methodologically strong studies that validated a 
psychometrically robust, generic neurodegenerative disease apathy scale. This was 
partly due to the unrepresentative samples, lack of standardizing selection criteria in 
the validation studies for generic neurodegenerative disease. Many of the studies 
validated scales in samples that were biased to dementia patients, with no studies 
including ALS patients. It may be difficult to design or validate such a generic scale 
due to practical difficulties of forming a broad and mixed neurodegenerative disease 
patient sample group. However, further well-constructed validation studies or newly 
developed scales are needed to explore if it is possible to assess apathy in generic 
neurodegenerative disease. 
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Supplementary Table S1. Guidelines for interpreting psychometric 
statistics (based on Hermans et al., 2011) 
Psychometric Statistic Interpretation 
Internal Consistency 
<0.50 
0.50-0.59 
0.60-0.69 
0.70-0.79 
0.80-0.89 
≥0.90 
 
 
Unacceptable 
Poor 
Questionable 
Acceptable 
Good 
Excellent 
Correlation Coefficients (Pearson’s product-moment and 
Spearman rank) 
<0.29 
0.30-0.49 
0.50-0.69 
0.70-0.89 
≥0.90 
 
 
 
Little or no correlation 
Low correlation 
Moderate correlation 
High correlation 
Very high correlation 
 
Intra-class Correlation Coefficient 
<0.40 
0.40-0.59 
0.60-0.74 
≥0.75 
 
 
Poor 
Fair 
Good 
Excellent 
 
Kappa Statistic 
<0.00 
0.00-0.20 
0.21-0.40 
0.41-0.60 
0.61-0.80 
0.81-1.00 
 
Poor 
Slight 
Fair 
Moderate 
Substantial 
Almost prefect 
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Structured 
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eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
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INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 to 7 
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METHODS   
Protocol and 
registration  
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Risk of bias in 
individual 
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Synthesis of 
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Risk of bias 
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RESULTS  
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Synthesis of 
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Risk of bias 
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22 Present results of any assessment of risk of bias across studies (see Item 15).  13 to 21 
Additional 
analysis  
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DISCUSSION   
Summary of 
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FUNDING  
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